medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2006, Número 5

<< Anterior

Rev Invest Clin 2006; 58 (5)


Aspectos metodológicos y éticos de la farmacogenómica en los ensayos clínicos aleatorizados

Castillejos-López MJ, García-Sancho MC, Torres-Espíndola LM, Pérez-Padilla JR

Idioma: Español
Referencias bibliográficas: 76
Paginas: 512-524
Archivo PDF: 100.69 Kb.


RESUMEN

Uno de los mayores avances de la medicina moderna se ha dado con el reporte en borrador de la secuencia del genoma humano. Esto ha traído como consecuencia nuevas opciones en el diseño de la investigación clínica, en especial en los ensayos clínicos aleatorizados (ECAs). La farmacogenómica que ha emergido como una herramienta poderosa para la predicción de efectos farmacológicos basados en el genotipo de los sujetos estudiados, promete ser de gran utilidad en los próximos años para el desarrollo de la industria farmacéutica. Cabe destacar que la integración actual de los métodos de la farmacogenómica a la investigación y desarrollo (I&D) de nuevos medicamentos, ofrece la perspectiva de una nueva era en la prescripción médica, con terapias más individualizadas, disminución de eventos adversos en los pacientes y además un desarrollo más rápido y costo-efectivo de nuevos medicamentos. Sin embargo, la aplicación de la farmacogenómica a la investigación clínica representa nuevas interrogantes metodológicas, éticas y sociales que tendrán que desarrollarse de igual manera, para permitir un uso legal de la información generada por los ECAs que incorporan información genética.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. McPherson JD, Marra M, Hillier L, Waterston RH, Chinwalla A, Wallis J, et al. A physical map of the human genome. The International Human Genome Mapping Consortium. Nature 2001; 409: 934-41.

  2. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291: 1304-51.

  3. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. Lancet 2001; 357: 1191-4.

  4. Stuart JP. Clinical Trials: A practical approach. Toronto: John Wiley & Sons; 1983.

  5. National Institutes of health: An Introduction to Clinical Trials. Disponible en: http://www.clinicaltrials.gov/ct/gui/info/whatis. [Consulta: Febrero 01, 2006].

  6. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286: 2270-9.

  7. Israili ZH. Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man. Annu Rev Pharmacol Toxicol 1979; 19: 25-52.

  8. Evans WE, McLeod HL. Pharmacogenomics, drug disposition, drug targets and side effects. N Engl J Med 2003; 348: 538-49.

  9. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8: 283-9.

  10. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429: 464-8.

  11. Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Tregouet D, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 2006; 79: 316-24.

  12. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62: 423-9.

  13. Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006; 4: 44-9.

  14. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin- induced cardiotoxicity. Circulation 2005; 112: 3754-62.

  15. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005; 11: 7328-33.

  16. Magnusson Y, Levin MC, Eggertsen R, Nystrom E, Mobini R, Schaufelberger M, et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 2005; 78: 221-31.

  17. Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004; 24: 613-17.

  18. Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004; 20: 303-10.

  19. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 547-52.

  20. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611-15.

  21. Evans W, Relling M. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.

  22. Rusnak JM, Kisabeth RM, Herbert DP, McNeil DM. Pharmacogenomics: a clinician’s primer on emerging technologies for improved patient care. Mayo Clin Proc 2001; 76: 299-309.

  23. Murray M. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr Drug Metab 2006; 7: 67-81.

  24. Ioannidis J, Lau J. Cap. 15: Integrating genetics into randomized controlled trials. In: Khoury MJ, Little, J, Burke W. Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health And Prevent Disease. Oxford University Press; 2004.

  25. Hiratsuka M, Kishikawa Y, Takekuma Y, Matsuura M, Narahara K, Inoue T, et al. Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet 2002; 17: 357-62.

  26. Cardon LR, Idury RM, Harris TJ, Witte JS, Elston RC. Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics 2000; 10: 503-10.

  27. Fijal BA, Hall JM, Witte JS. Clinical trials in the genomic era: effects of protective genotypes on sample size and duration of trial. Control Clin Trials 2000; 21: 7-20.

  28. Syvanen A. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet 2001; 2: 930-42.

  29. Tsuchihashi Z, Dracopoli NC. Progress in high throughput SNP genotyping methods. Pharmacogenomics J 2002; 2: 103-10.

  30. Peters GJ, Smorenburg CH, Van Groeningen CJ. Prospective clinical trials using a pharmacogenetic/pharmacogenomic approach. J Chemother 2004; 16(Suppl. 4): 25-30.

  31. Kirkwood SC, Hockett RD Jr. Pharmacogenomic biomarkers. Dis Markers 2002; 18: 63-71.

  32. Kuhn J, Jones S, Hein D, Willcutt N, Greco F, Raefsky E, et al. A phase I pharmacokinetic, pharmacogenomic trial of weekly amonafide in patients with solid tumors. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22(14S July 15 Supplement): 2023.

  33. Rioux P. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am J Health Syst Pharm 2000; 57: 887-98.

  34. Murphy M, Beaman ME, Clark LS, Cayouette M, Benson L, Morris DM, et al. Prospective CYP2D6 genotyping as an exclusion criterion for enrolment of a phase III clinical trial. Pharmacogenetics 2000; 10: 583-90.

  35. O’Kane DJ, Weinshilboum RM, Moyer TP. Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics 2003; 4: 1-4.

  36. Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos. Disponible en: http://www.wma.net/e/policy/b3.htm [Consulta: Octubre 03, 2005].

  37. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. N Engl J Med 1982; 306: 1332-7.

  38. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. BMJ 2000; 321: 504.

  39. Even C, Siobud-Dorocant E, Dardennes RM. Critical approach to antidepressant trials. Blindness protection is necessary, feasible and measurable. Br J Psychiatry 2000; 177: 47-51.

  40. Brem R, Cox DG, Chapot B, Moullan N, Romestaing P, Gerard JP, et al. The XRCC1 -77T > C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage. Carcinogenesis 2006; 0: bgl114v1.

  41. Filippi AR, Franco P, Ricardi U. Is clinical radiosensitivity a complex genetically controlled event? Tumori 2006; 92: 87-91.

  42. Crews KR. Individualizing chemotherapeutic treatment of colorectal cancer. Am J Health Syst Pharm 2006; 63(9 Suppl. 2): S12-S17.

  43. Tomao F, Miele E, Spinelli GP, Russillo M, La Ferla G, Tomao S. Trastuzumab in metastatic breast cancer. Eur J Gynaecol Oncol 2006; 27: 247-9.

  44. Chen S, Kumar S, Chou WH, Barrett JS, Wedlund PJ. A genetic bias in clinical trials? Cytochrome P450-2D6 (CYP2D6) genotype in general vs. selected healthy subject populations. Br J Clin Pharmacol 1997; 44: 303-4.

  45. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002; 20: 2495-9.

  46. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001; 323: 42-6.

  47. Szolnoki Z, Melegh B. Gene-gene and gene-environment interplay represent specific susceptibility for different types of ischaemic stroke and leukoaraiosis. Curr Med Chem 2006; 13: 1627-34.

  48. Hayes RB. Genetic susceptibility and occupational cancer. Med Lav 1995; 86: 206-13.

  49. Sugimura T, Kumimoto H, Tohnai I, Fukui T, Matsuo K, Tsurusako S, et al. Gene-environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med 2006; 35: 11-8.

  50. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 1999; 56: 247-58.

  51. Spielberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996; 24: 509-19.

  52. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 2003; 4: 415-22.

  53. Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol 2005; 23: 4450-57.

  54. Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov 2002; 1: 300-8.

  55. Roses AD. Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 2002; 1: 541-9.

  56. Phillips KA, Veenstra DL, Van Bebber S, Sakowski J. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 2003; 4: 231-9.

  57. Higashi MK, Veenstra DL. Managed care in the genomic era: assessing the cost effectiveness of genetic test. Am J Manag Care 2003; 9: 493-500.

  58. World Health Organization. Review of Ethical Issues in Medical Genetics 2003; Disponible en: http://www.who.int/genomics/publications/en/index.html [Consulta: Febrero 01, 2006]

  59. National Human Genome Research Institute. Ethical, Legal and Social Implications (ELSI) Program Publications and Products. Disponible en: http://www.nhgri.nih.gov/PolicyEthics [Consulta: Febrero 01, 2006]

  60. Expert Group and public citizens and stakeholder conference on ethical, legal and social aspects of genetic testing Disponible en: http://www.eu.int/comm/research/conferences/ 2004/genetic/pdf/recommendations_en.pdf [Consulta: Febrero 01, 2006]

  61. Issa AM, Keysserlingk EW. Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer’s disease: emerging ethical issues. Can J Psychiatry 2000; 45: 917-22.

  62. Sarma V. Medical research. Mandatory ethics recommendations. Nature 1983; 301: 103.

  63. McHale JV. Guidelines for medical research –some ethical and legal problems. Med Law Rev 1993; 1: 160-85.

  64. Dhai A. Research ethics review –protecting participants in research. S Afr Med J 2005; 95: 595-7.

  65. AmpliChip CYP450 Test. The Medical Letter Inc. Med Lett Drugs Ther 2005; 47: 71-2.

  66. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15-27.

  67. Day RO, Birkett DJ, Miners J, Shenfield GM, Henry DA, Seale JP. Access to medicines and high-quality therapeutics: global responsibilities for clinical pharmacology. A major theme of the 2004 World Congress of Clinical Pharmacology and Therapeutics was worldwide equity of access to medicines. Med J Aust 2005; 182: 322-3.

  68. Ahmad K. Access denied to essential medicines in developing world. Lancet Infect Dis 2002; 2: 711.

  69. Rojo P. Access to essential drugs in developing countries Gac Sanit 2001; 15: 540-5.

  70. Morel CM, Acharya T, Broun D, Dangi A, Elias C, Ganguly NK, et al. Health innovation networks to help developing countries address neglected diseases. Science 2005; 309: 401-4.

  71. Reich MR. The global drug gap. Science 2000; 287: 1979-81.

  72. Pal SK, Mittal B. Fight against cancer in countries with limited resources: the post-genomic era scenario. Asian Pac J Cancer Prev 2004; 5: 328-33.

  73. World Health Organization. World Health Report 2002: Reducing Risks, Promoting Healthy Life. Disponible en: http://www.who.int/whr/2002/en/. [Consulta: Febrero 01, 2006]

  74. Starfield B, Shi L. Policy relevant determinants of health: an international perspective. Health Policy 2002; 60: 201-18.

  75. Chabalgoity JA. Paving the way for the introduction of new vaccines into developing countries. Expert Rev Vaccines 2005; 4: 147-50.

  76. Schieber G, Maeda A. Health care financing and delivery in developing countries. Health Aff (Millwood) 1999; 18: 193-205.




2020     |     www.medigraphic.com